



# Molecular surveillance of mutations in the Cytochrome b gene of *Plasmodium falciparum* in Gabon and Ethiopia

Tamirat Gebru,<sup>1,4</sup> Asrat Hailu,<sup>3</sup> Peter G Kremsner,<sup>2,4</sup> Jürgen FJ Kun,<sup>4</sup> and Martin P Grobusch<sup>2</sup>

1 Faculty of Health Sciences, Haramaya University, Harar, Ethiopia

2 Albert Schweitzer Hospital, Lambaréné, Gabon

3 Addis Ababa University, Addis Ababa, Ethiopia

4 Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany

5 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa



# Objectives



- To detect and determine the prevalence of Cytochrome b gene mutation associated with Atovaquone resistance in *P. falciparum* in the blood specimen collected from patients with uncomplicated malaria in Gabon and Ethiopia.



# Methods



- Clinical material (blood) from both study sites
- DNA extraction using QIA amp<sup>®</sup> DNA Mini Kit
- Samples were analyzed using PCR and DNA sequencing to detect variation in the *cyt b* gene
- **Primers for Gabon** samples to amplify a 939 bp fragment containing the *cyt b* gene:
  - *Cytb1* (5' – CTCTATTAATTTAGTTAAAGCACAC – 3') and
  - *Cytb4* (5' – ACAGAATAATCTCTAGCACC - 3')
- Obtained fragments were analysed on a 1% agarose gel for purity
- Gels were stained with CYBR<sup>®</sup> GREEN I and visualized on a dark reader trans-illuminator



# Methods



- Prior to sequencing, the amplified DNA was purified by a PCR purification kit
- DNA sequence was determined using Big Dye 1.1<sup>®</sup> and purified again by DNA grade sephadex<sup>®</sup>
- Strand separation was done on an Applied Biosystems Genetic Analyzer 3100<sup>®</sup>
- DNA sequences were finally analysed with the Bio-edit<sup>®</sup> sequence alignment program to detect point mutations
- **Primers for Ethiopia** samples to amplify a 939 bp fragment containing the *cyt b* gene:
  - *CytbF* (5' – GGGTATGATACAGCATTAAAAATAC – 3') and
  - *Cytb4* resulting in a 349 bp fragment
- Here we were interested only in the 3' end of the gene since no mutations were detected in the 5' end in the Gabonese samples



# Results



- 4/40 (10%) mutant types (4 various polymorphisms leading to an amino acid change from M to I in one single case) in Gabonese isolates
- 141/141 wild type isolates from Ethiopia



# Results



## Prevalence of wild and mutant type in the cytochrome b gene of *Plasmodium falciparum* isolates from Gabon and Ethiopia

| country of origin | number of isolates | wild type | mutation <sup>1,2</sup>          | amino acid change           |
|-------------------|--------------------|-----------|----------------------------------|-----------------------------|
| Ethiopia          | 141                | 141       | n. a.                            | n. a.                       |
| Gabon             | 40                 | 36        | T676A<br>C689T<br>T760G<br>G925T | ---<br>---<br>---<br>M to I |

n.a. = not applicable

<sup>1</sup>all SNP were found in one sample each

<sup>2</sup>no mutations found in codon 268



# Discussion & Conclusions



- initial reports of definite, or possible, resistance-conferring cyt b gene polymorphisms were in isolates from tx-failing travellers from Thailand and Nigeria (Tyr268Asn and Tyr268Ser) and in other codons (only *in vitro*) (Korsinsky et al 2000, Fivelman 2002)
- mutations in codon 268 have been recognized as potential markers to measure and control the emergence of resistance against A/P
- however, *in vivo* A/P resistance may not always be associated with cyt b mutations (Wichmann et al. 2004) since failure in drug action can also be resulting from metabolic diversion to the alternative respiratory pathway of the parasite (Thapar et al. 2005)
- no resistance-conferring mutations found *in vitro* and on sequencing of 37 isolates from Cameroon (Basco et al. 2003)
- none of 100 isolates from Northern Ghana exhibited resistance-conferring polymorphisms in codon 268 (Muehlen et al. 2004)



# Future perspectives



- Many other findings are well in line with our own results.
- In the absence of drug pressure, spontaneous and possible resistance-conferring mutations are rare.
- However, a higher rate of resistance in the future is likely to occur under drug pressure
- Like aminoquinoline and sulpha drugs, possibly resistance-confirming polymorphisms (single, or in combination) will occur with almost certainty.